ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,492Medicare Part D Prescriptions Filled, Including Refills

Rank: 106 out of 917

$549K Total Retail Price of All Prescriptions

Rank: 90 out of 917

649 Patients Receiving at Least One Drug in Part D
81%Patients 65 Years and Older
38% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Washington
Lower avg

Schedule Two
Controlled Substances

10% of this provider’s 649 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

11% of this provider’s 649 patients filled at least one prescription for a schedule three drug, compared to an average of 10%.

Risky Drugs to Seniors

2% of this provider’s 7,075 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

19% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$58 was the average price of a prescription from this provider, compared to $56 among peers.

Prescriptions per Patient

15 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Washington
LISINOPRIL 453 372 1 1
SIMVASTATIN 382 287 2 2
ATENOLOL 365 278 3 12
OMEPRAZOLE 361 272 4 4
LEVOTHYROXINE SODIUM 339 278 5 3
AMLODIPINE BESYLATE 299 254 6 5
HYDROCODONE-ACETAMINOPHEN 234 146 S3 7 6
ATORVASTATIN CALCIUM 230 172 8 14
METFORMIN HCL 197 153 9 8
HYDROCHLOROTHIAZIDE 195 168 10 9
FUROSEMIDE 171 143 11 7
PRAVASTATIN SODIUM 156 140 12 20
ALENDRONATE SODIUM 150 148 13 23
LOSARTAN POTASSIUM 144 122 14 13
GABAPENTIN 138 104 15 17
METOPROLOL TARTRATE 135 126 16 11
ALLOPURINOL 112 82 17 31
TAMSULOSIN HCL 111 80 18 25
ZOLPIDEM TARTRATE 104 67 19 21
FLUTICASONE PROPIONATE 100 79 20 26
POTASSIUM CHLORIDE 99 79 21 16
CITALOPRAM HBR 99 69 21 15
RANITIDINE HCL 99 65 21 29
OXYCODONE-ACETAMINOPHEN 98 67 S2 24 46
WARFARIN SODIUM 91 86 25 10
FLUOXETINE HCL 91 90 25 38
LOVASTATIN 89 63 27 19
SERTRALINE HCL 78 49 28 24
PROAIR HFA 74 38 29 35
DOXAZOSIN MESYLATE 73 51 30 74
LANTUS 72 43 31 37
GLYBURIDE 72 69 R 31 71
PREDNISONE 72 53 31 34
FINASTERIDE 70 68 34 77
TRIAMTERENE-HCTZ 68 52 35 36
RISPERIDONE 68 44 35 51
LANTUS SOLOSTAR 66 48 37 63
CRESTOR 65 55 38 30
TRAMADOL HCL 64 29 39 28
OXYCODONE HCL 61 14 S2 40 27
PAROXETINE HCL 61 48 40 57
TRAZODONE HCL 58 43 42 22
METOPROLOL SUCCINATE 57 53 43 18
HYDRALAZINE HCL 57 56 43 90
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on March 1, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.